Toward an integrated treatment of schizophrenia.
نویسنده
چکیده
Schizophrenia has baffled psychiatrists since its nosological identification by Kraepelin in 1896. In the study of schizophrenia, adherents of biochemical, psychophysiological, and psychological etiologies have vied to exert the primacy of their orientations. Different explanatory levels are not in conflict when a general systems approach is used as suggested by Grinker (I969 and in press). General systems theory may eventually provide the most comprehensive understanding of schizophrenia, but in the meantime, it is necessary to isolate our perspectives and study each of them thoroughly, with integration as our eventual goal. In this report, a psychological perspective will be maintained in deriving treatment principles from schizophrenics who have thus far shown an enduringly good outcome. Although biochemical, neurophysiological, psychophysiological, and other perspectives will not be considered here, their absence does not at all imply that they are less central to understanding the treatment of this grave disorder. In my previous report on a group of 13 young adult schizophrenics (Kayton 1973), good outcome was sustained up to 5.5 years after hospital discharge. "Good outcome" was defined as a decided increase in social and vocational functioning as well as a greatly improved self-appraisal and a marked diminution in the intensity of schizophrenic symptoms. The scale devised by Strauss and Carpenter (1972), which is a measure of social and vocational adjustment as well as frequency of symptoms and rehospitalizations, corroborated the clinical impres-
منابع مشابه
Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial
Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...
متن کاملHerbal Medicine in the Treatment of Schizophrenia: A Review
As a chronic psychiatric disorder, schizophrenia affects the worldwide population with a lifetime prevalence of 1% and considerable long-term mortality, morbidity, and burden. Besides the adverse effects of routine treatment regimens, a significant portion of patients remain symptomatic despite treatment, especially those with negative symptoms which are the major disabling factors in these pat...
متن کاملP136: Role of Muscarinic Receptors in Schizophrenia
Schizophrenia is a severe psychiatric illness with a lifetime prevalence of ˜1% that imposes a huge toll on patients, their families and public health services worldwide. Delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior and negative symptoms constitute the core symptoms of schizophrenia. Although the neurotransmitter dopamine plays a prominent role in t...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملEfficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial
Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Schizophrenia bulletin
دوره 12 شماره
صفحات -
تاریخ انتشار 1975